AI-generated · cited to primary sources · not investment advice
Eli Lilly and Company Common Stock (LLY) Jun 2025 Filing Analysis
Does management do what it says?
The unfunded commitment target was lowered to $850 million, indicating a reduction in future cash outflow obligations. (1 revised across 1 tracked commitment)
“while decreasing income tax payments during the second half of 2025.”
See the full cited Management analysis of Eli Lilly and Company Common Stock
Where does growth come from?
R&D investment is accelerating as the company advances its late-stage pipeline. R&D expenses grew 23% in Q2 2025 and 16% for the first half of 2025, reflecting increased investment in early and late-stage portfolios to sustain long-term growth. (1 accelerating across 1 signal)
“Research and development expenses increased 23 percent and 16 percent for the three and six months ended June 30, 2025, respectively, driven by continued investments in our early and late-stage portfolio.”
See the full cited Future Growth analysis of Eli Lilly and Company Common Stock
What could break the thesis?
The risk remains stable but significant; U.S. realized prices fell by 8% in the first half of 2025, primarily driven by Mounjaro and Zepbound, despite massive volume growth. (1 stable)
“In the U.S. for the three and six months ended June 30, 2025, the volume increase and the lower realized prices were driven by Zepbound and Mounjaro. ... Price (8)% [for U.S. 2025 vs 2024].”
See the full cited Risk analysis of Eli Lilly and Company Common Stock
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.